Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6335815 | 0.81 | HTT (0.67) | ALDH1A1MAPTHTTKMT2ACYP2C19 | |
| SCHEMBL3310495 | 0.81 | MC4R (0.58) | ALDH1A1MAPTTSHRHTTKMT2A | |
| SCHEMBL6752179 | 0.80 | HTT (0.65) | ALDH1A1HTTKMT2ACYP2C19MEN1 | |
| SCHEMBL6749008 | 0.80 | HTT (0.65) | ALDH1A1HTTKMT2ACYP2C19MEN1 | |
| SCHEMBL6749288 | 0.80 | HTT (0.65) | ALDH1A1MAPTHTTKMT2ACYP2C19 | |
| SCHEMBL6965515 | 0.79 | HTT (0.85) | ALDH1A1MAPTHTTKMT2ACYP2C19 | |
| SCHEMBL19734218 | 0.77 | NPSR1 (0.61) | ALDH1A1MAPTHTTKMT2ACYP2C19 | |
| SCHEMBL31097554 | 0.77 | ALDH1A1 (0.61) | ALDH1A1MAPTTSHRHTTKMT2A | |
| SCHEMBL27162554 | 0.77 | ALDH1A1 (0.61) | ALDH1A1MAPTTSHRHTTKMT2A | |
| SCHEMBL13102870 | 0.77 | HTT (0.61) | ALDH1A1HTTKMT2ACYP2C19ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513237-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120178741-A1 | Sulfonylamino-Derivatives As Novel Inhibitors Of Histone Deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-12 | — | — | US | disclosed |
| US-8163733-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-24 | — | — | US | disclosed |
| US-20100234353-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-16 | — | — | US | disclosed |
| US-7767679-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-03 | — | — | US | disclosed |
| EP-1485354-B1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-28 | — | — | EP | disclosed |
| CN-1305850-C | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2007-03-21 | — | — | CN | disclosed |
| US-20050171347-A1 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-08-04 | — | — | US | disclosed |
| CN-1642912-A | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2005-07-20 | — | — | CN | disclosed |
| EP-1485354-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076401-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234353-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | ALDH1A1 1350/4885MAPT 3878/4885TSHR 909/4885 |
| US-20050171347-A1 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | ALDH1A1 1350/4885MAPT 3878/4885TSHR 909/4885 |
| US-20120178741-A1 | Sulfonylamino-Derivatives As Novel Inhibitors Of Histone Deacetylase | HDAC1, HDAC3, HDAC11 | ALDH1A1 1350/4885MAPT 3878/4885TSHR 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.